Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial

OBJECTIVE: To determine the occurrence of extremely low HDL cholesterol (HDL-C) among participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial and to examine the relationship of this finding with treatment with fenofibrate and thiazolidinedione (TZD). RESEARCH DESIG...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Linz, Peter E., Lovato, Laura C., Byington, Robert P., O’Connor, Patrick J., Leiter, Lawrence A., Weiss, Daniel, Force, Rex W., Crouse, John R., Ismail-Beigi, Faramarz, Simmons, Debra L., Papademetriou, Vasilios, Ginsberg, Henry N., Elam, Marshall B.
Format: Artigo
Idioma:Inglês
Publicat: American Diabetes Association 2014
Matèries:
Clinical Care/Education/Nutrition/Psychosocial Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3931389/
https://ncbi.nlm.nih.gov/pubmed/24296848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc13-0790
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars